Vaxcyte COO Jim Wassil sells 18,000 shares

The COO's sale was made under a Rule 10b5-1 trading plan adopted December 9, 2025; the option was fully vested and exercisable.

Rhea-AI Filing Summary

Vaxcyte, Inc. executive Jim Wassil (EVP, Chief Scientific Ofc, COO) exercised options covering 18,000 shares of common stock at an exercise price of $5.35 per share on October 5, 2026, and sold 18,000 shares at $86.74 per share that day. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. The option was fully vested and exercisable, and the reported position following exercise was 46,398 stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 18,000 shares ($1.47M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Wassil Jim

Role EVP, Chief Scientific Ofc, COO

Sold 18,000 shs ($1.56M)

Approx. gross sale proceeds $1.56M

Approx. exercise cost $96K

Approx. pre-tax spread $1.47M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F2	18,000	$0.00	$0.00
Exercise	Common Stock	18,000	$5.35	$96K
Sale	Common Stock F1	18,000	$86.74	$1.56M

Holdings After Transaction: Stock Option (right to buy) — 46,398 contracts (Direct); Common Stock — 145,435 shares (Direct)

Footnotes (2)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
2. F2. Stock Option is fully vested and exercisable.

Key Figures

Options exercised: 18,000 shares Exercise price: $5.35 per share Shares sold: 18,000 shares +2 more

5 metrics

Options exercised 18,000 shares October 5, 2026

Exercise price $5.35 per share October 5, 2026

Shares sold 18,000 shares October 5, 2026

Sale price $86.74 per share October 5, 2026

Stock options following exercise 46,398 stock options Reported following the October 5, 2026 exercise

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), exercise price

3 terms

Rule 10b5-1 trading plan regulatory

"sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) technical

"Stock Option is fully vested and exercisable"

exercise price financial

"at an exercise price of $5.3500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCVX shares did Jim Wassil sell, and at what price?

Jim Wassil sold 18,000 shares of Vaxcyte common stock at $86.74 per share on October 5, 2026. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

What were the PCVX option exercise terms reported by Jim Wassil?

Wassil exercised options covering 18,000 shares of common stock at an exercise price of $5.35 per share on October 5, 2026. The option was fully vested and exercisable, and his reported position following exercise was 46,398 stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:09 PM Accepted by SEC EDGAR 10/07/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Ofc, COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		M		18,000	A	$5.35	163,435	D
Common Stock	10/05/2026		S(1)		18,000	D	$86.74	145,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.35	10/05/2026		M			18,000	(2)	04/17/2030	Common Stock	18,000	$0	46,398	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

2. Stock Option is fully vested and exercisable.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)